|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Barr_Pharmaceuticals
gptkb:Merck_KGaA's_generics_business
Cephalon
Actavis Generics
Ratiopharm
Allergan's generics business
|
|
gptkbp:CEO
|
Kåre Schultz
|
|
gptkbp:challenges
|
competition
regulatory scrutiny
patent expirations
market access issues
pricing pressures
|
|
gptkbp:clinicalTrials
|
ongoing
completed
planned
|
|
gptkbp:employees
|
over 40,000
|
|
gptkbp:founded
|
1901
|
|
gptkbp:founder
|
gptkb:Eli_Hurvitz
|
|
gptkbp:global_presence
|
over 60 countries
|
|
gptkbp:headquarters
|
Petah_Tikva,_Israel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Teva
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:market
|
global
approximately $10 billion (2021)
|
|
gptkbp:market_segment
|
growing
significant
|
|
gptkbp:operations
|
Richard_Francis
|
|
gptkbp:partnerships
|
gptkb:Mylan
gptkb:Boehringer_Ingelheim
gptkb:Pfizer
|
|
gptkbp:patentCitation
|
numerous
|
|
gptkbp:philanthropy
|
gptkb:Teva_Foundation
|
|
gptkbp:products
|
generic drugs
specialty medicines
|
|
gptkbp:research
|
gptkb:Michael_Hayden
|
|
gptkbp:research_focus
|
neurology
oncology
pain management
women's health
respiratory diseases
|
|
gptkbp:revenue
|
$16.7 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
gptkb:TEVA
|
|
gptkbp:subsidiary
|
gptkb:Teva_Pharmaceuticals_USA
gptkb:Teva_Canada_Limited
gptkb:Teva_UK_Limited
gptkb:Teva_Pharmaceuticals_Europe_B.V.
|
|
gptkbp:sustainability_initiatives
|
community engagement
ethical business practices
employee well-being
environmental responsibility
|